MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 17, 2024

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2030

Conditions
Relapse Multiple MyelomaRefractory Multiple Myeloma
Interventions
DRUG

Teclistamab Monotherapy

standard of care

DRUG

Teclistamab

investigational doses compared to SOC

Trial Locations (13)

10022

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10029

RECRUITING

Mt. Sinai School of Medicine, New York

28203

RECRUITING

Atrium Levine Cancer Institute, Charlotte

30322

RECRUITING

Emory Winship Cancer Center, Atlanta

37203

RECRUITING

Tennessee Oncology, Nashville

48201

RECRUITING

Barbara Ann Karmanos Cancer Center, Detroit

55905

NOT_YET_RECRUITING

Mayo Clinic Rochester, Rochester

60637

RECRUITING

University of Chicago Cancer Center, Chicago

63110

RECRUITING

Washington University Medicine, St Louis

91010

RECRUITING

City of Hope, Duarte

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana Farber Cancer Institute/Harvard Medical School, Boston

07601

RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Multiple Myeloma Research Consortium

NETWORK